Home Online Features In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease
In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson’s Disease
Press Releases
Right Brain Bio, Inc.  
March 11, 2025

In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson’s Disease

WESTCHESTER COUNTY, N.Y. and MONMOUTH JUNCTION, N.J., March 11, 2025 /PRNewswire/ -- Right Brain Bio, a biotechnology company pioneering treatments for complex diseases, today announced a manufacturing agreement with Suven

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social